Last update Aug. 22, 2019
Very Low Risk
Selective agonist for the vascular receptor of 5-hydroxytryptamine-1 (5-HT1, serotonin) with vasoconstrictor action at the intracranial level.
Indicated in acute migraine attack.
Oral administration in a daily dose.
It is excreted in breastmilk in clinically insignificant amounts: 0.02% of the maternal dose (AEMPS-Pfizer 2013).
Its low oral bioavailability impedes its transfer from breastmilk into infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
Several expert authors consider its use to be safe or probably safe during breastfeeding (Hale 2019, Briggs 2017, Amundsen 2015, Davanzo 2014, Hutchinson 2013, Duong 2010).
Its use, usually in isolated doses, makes the occurrence of adverse effects in infants unlikely (Jürgens 2009).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM